Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Citi
Accenture
Cantor Fitzgerald
Moodys
Healthtrust
Fuji
UBS
Deloitte

Generated: April 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,239,173

« Back to Dashboard

Summary for Patent: 6,239,173
Title: 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor
Abstract:The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
Inventor(s): Wang; Zhaoyin (Pierrefond, CA), Therien; Michel (Laval, CA)
Assignee: Merck Frosst Canada Inc./Merck Frosst Canada & Co. (Kirkland, CA)
Application Number:09/443,000
Patent Claims: 1. A compound which is 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone.

2. A method of treating an inflammatory disease in a human patient in need of such treatment comprising administering a non-toxic therapeutically effective amount of 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone and a pharmaceutically acceptable carrier.

3. A method of treating a cyclooxygenase-2 mediated disease in a human patient in need of such treatment comprising administering a non-toxic therapeutically effective amount of 3-phenyl-4-(4-(methylsulfonylphenyl)-2-(5H)-furanone and a pharmaceutically acceptable carrier.

4. A method according to claim 2 of treating arthritis in a human patient in need of such treatment comprising administering a non-toxic therapeutically effect amount of 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone and a pharmaceutically acceptable carrier.

5. A method according to claim 2 of treating rheumatoid arthritis in a human patient in need of such treatment comprising administering a non-toxic therapeutically effective amount of 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone and a pharmaceutically acceptable carrier.

6. A method according to claim 2 of treating osteoarthritis in a human patient in need of such treatment comprising administering a non-toxic therapeutically effective amount of 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone and a pharmaceutically acceptable carrier.

7. A method according to claim 2 of treating pain in a human patient in need of such treatment comprising administering a non-toxic therapeutically effective amount of 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone and a pharmaceutically acceptable carrier.

8. A method according to claim 2 of treating fever in a human patient in need of such treatment comprising administering a non-toxic therapeutically effect amount of 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone and a pharmaceutically acceptable carrier.

9. A method according to claim 2 of treating dysmenorrhea in a human patient in need of such treatment comprising administering a non-toxic therapeutically effective amount of 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone and a pharmaceutically acceptable carrier.

10. A pharmaceutical compostion comprising 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone and a pharmaceutically acceptable carrier.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
QuintilesIMS
US Department of Justice
Cerilliant
Johnson and Johnson
Fish and Richardson
Merck
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.